A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.

被引：1
|
作者：
Coleman, Robert L.
Concin, Nicole
Herzog, Thomas J.
Woelber, Linn Lena
Mirza, Mansoor Raza
Monk, Bradley J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS5601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5601
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
    Vergote, I.
    Dean, E.
    Lassen, U.
    de Bono, J.
    Drew, Y.
    Machiels, J-P.
    Nielsen, D.
    Arkenau, H-T.
    Forster, M.
    Jones, R.
    Slomovitz, B.
    Spicer, J.
    Johnson, M.
    Cornez, N.
    Gennigens, C.
    Fulton, B.
    Lisby, S.
    Basse, L.
    Coleman, R.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
    Hong, David S.
    Concin, Nicole
    Vergote, Ignace
    de Bono, Johann S.
    Slomovitz, Brian M.
    Drew, Yvette
    Arkenau, Hendrik-Tobias
    Machiels, Jean-Pascal
    Spicer, James F.
    Jones, Robert
    Forster, Martin D.
    Cornez, Nathalie
    Gennigens, Christine
    Johnson, Melissa L.
    Thistlethwaite, Fiona C.
    Rangwala, Reshma A.
    Ghatta, Srinivas
    Windfeld, Kristian
    Harris, Jeffrey R.
    Lassen, Ulrik Niels
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1220 - 1228
  • [3] A PHASE IIA STUDY OF TISOTUMAB VEDOTIN ((HuMax®-TF-ADC) IN PATIENTS WITH RELAPSED, RECURRENT AND/OR METASTATIC CERVICAL CANCER: UPDATED SAFETY AND EFFICACY
    Concin, N.
    Vergote, I.
    Dean, E.
    Lassen, U.
    De Bono, J.
    Drew, Y.
    Machiels, J. P.
    Nielsen, D.
    Arkenau, T.
    Forster, M.
    Jones, R.
    Slomovitz, B.
    Spicer, J.
    Johnsson, M.
    Cornez, N.
    Gennigens, C.
    Fulton, B.
    Rangwala, R.
    Coleman, R.
    Hong, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1971 - 1971
  • [4] Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA
    Kim, Esther S.
    Al-Salama, Zaina T.
    DRUGS & THERAPY PERSPECTIVES, 2022, 38 (09) : 382 - 388
  • [5] Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA
    Esther S. Kim
    Zaina T. Al-Salama
    Drugs & Therapy Perspectives, 2022, 38 : 382 - 388
  • [6] A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
    Concin, N.
    Vergote, I. B.
    Lassen, U. N.
    Drew, Y.
    Machiels, J-P.
    Arkenau, H-T.
    Forster, M. D.
    Jones, R.
    Johnson, M. L.
    Slomovitz, B. M.
    Spicer, J.
    Cornez, N.
    Gennigens, C.
    Coleman, R. L.
    Windfeld, K.
    Ghatta, S.
    Rangwala, R. A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2018, 29 : 344 - 344
  • [7] Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
    Coleman, Robert L.
    Lorusso, Domenica
    Gennigens, Christine
    Gonzalez-Martin, Antonio
    Randall, Leslie
    Cibula, David
    Lund, Bente
    Woelber, Linn
    Pignata, Sandro
    Forget, Frederic
    Redondo, Andres
    Vindelov, Signe Diness
    Chen, Menghui
    Harris, Jeffrey R.
    Smith, Margaret
    Nicacio, Leonardo Viana
    Teng, Melinda S. L.
    Laenen, Annouschka
    Rangwala, Reshma
    Manso, Luis
    Mirza, Mansoor
    Monk, Bradley J.
    Vergote, Ignace
    LANCET ONCOLOGY, 2021, 22 (05): : 609 - 619
  • [8] Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
    Coleman, R. L.
    Lorusso, D.
    Gennigens, C.
    Gonzalez-Martin, A.
    Randall, L.
    Cibula, D.
    Lund, B.
    Woelber, L.
    Pignata, S.
    Forget, F.
    Redondo, A.
    Rangwala, R.
    Vindelov, S. D.
    Chen, M.
    Harris, J. R.
    Nicacio, L.
    Teng, M. S. L.
    Smith, M.
    Monk, B. J.
    Vergote, I. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1162 - S1163
  • [9] Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.
    Enzinger, Peter C.
    McCleary, Nadine Jackson
    Horick, Nora
    Cleary, James M.
    Rubinson, Douglas Adam
    Fitzpatrick, Bridget
    Graham, Christopher
    Clark, Jeffrey W.
    Patel, Anuj K.
    Pectasides, Eirini
    Perez, Kimberly
    Yurgelun, Matthew B.
    Azzoli, Christopher G.
    Enzinger, Andrea Catherine
    Gainor, Justin F.
    Schlechter, Benjamin L.
    Meyerhardt, Jeffrey A.
    Ng, Kimmie
    Bass, Adam Joel
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)
    Hong, D. S.
    Arkenau, H. T.
    de Bono, J.
    Lassen, U. N.
    Drew, Y.
    Slomovitz, B. M.
    Ghatta, S.
    Windfeld, K.
    Rangwala, R. A.
    Concin, N.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 11 - 12
12345